ÎÚÑ»´«Ã½

President
Mohandas Narla, DSc, New York Blood Center
Consultancy for Forma Therapeutics and New York Blood Center; Honoraria from National Institutes of Health; ÎÚÑ»´«Ã½ on a Board or Advisory Committee for Canadian Blood Services; Patents & Royalties from Lawrence Berkeley National Laboratory and UpToDate; Research Funding from National Institutes of Health.

President-Elect
Belinda Avalos, MD, Atrium Health Levine Cancer Institute
ÎÚÑ»´«Ã½ on a Board or Advisory Committee for Juno CAR-T cell Advisory Board; and Patents & Royalties from BMJ Best Practice.

Vice President
Robert Negrin, MD, Stanford University
Consultancy and Equity Ownership (multiple companies), ÎÚÑ»´«Ã½ on a Board or Advisory Committee DSMB for a clinical study of CAR T cells.

Secretary
Cynthia E. Dunbar, MD, National Institutes of Health
Research funding from Be Bio, Disc Medicine, and Novartis; Honoraria from UpToDate.

Treasurer
Joseph R. Mikhael, MD, FRCPC, MEd, Translational Genomics Research Institute
Honoraria from Amgen, GSK, Janssen, Karyopharm, Sanofi, and Takeda; and Consultancy for BMS and Pfizer.

Blood Editor-in-Chief
Nancy Berliner, MD, Brigham and Women's Hospital
Honoraria from UpToDate.

Blood Advances Editor-in-Chief
Catherine M. Bollard, MD, Children's National Medical Center
Equity Ownership of Caballeta Bio, Mana Therapeutics, Neximmune, and Repertoire; ÎÚÑ»´«Ã½ on a Board or Advisory Committee for Caballeta Bio, Catamaran Bio, Mana Therapeutics, and SOBI; Patents & Royalties from Mana Therapeutics; Consultancy for Neogene and Roche; and Honoraria from Neogene, Roche, and SOBI.

Executive Director
Martha Liggett, ÎÚÑ»´«Ã½
Indicated no conflicts of interest.

Deputy Executive Director
Matthew Gertzog, ÎÚÑ»´«Ã½
Equity ownership of Amgen.